Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy

MedXY Editorial Team•Sep 19, 2026•Cardiology

Comprehensive proteomic and metabolomic profiling reveals 203 proteins and 16 metabolites significantly associated with cardiac structure and function in breast cancer patients undergoing anthracycline and/or trastuzumab therapy.
Cathepsin C identified as a key protein linked to left ventricular ejection fraction (LVEF), longitudinal strain, left atrial volume index, and incident cardiac dysfunction.
Enriched pathways include protein deubiquitination, protein modification, macromolecule catabolic processes, and global metabolic pathways, underscoring complex biological mechanisms underlying cardiotoxicity.
Amino acid–related metabolites such as n-acetylglutamine and aspartic acid show strong associations with reductions in cardiac function metrics, pointing to metabolic alterations during cardiotoxic therapy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Comprehensive proteomic and metabolomic profiling reveals 203 proteins and 16 metabolites significantly associated with cardiac structure and function in breast cancer patients undergoing anthracycline and/or trastuzumab therapy.
Cathepsin C identified as a key protein linked to left ventricular ejection fraction (LVEF), longitudinal strain, left atrial volume index, and incident cardiac dysfunction.
Enriched pathways include protein deubiquitination, protein modification, macromolecule catabolic processes, and global metabolic pathways, underscoring complex biological mechanisms underlying cardiotoxicity.
Amino acid–related metabolites such as n-acetylglutamine and aspartic acid show strong associations with reductions in cardiac function metrics, pointing to metabolic alterations during cardiotoxic therapy.